Caroline Seymour
Articles
Mitazalimab Plus mFOLFIRINOX Boosts Responses in Previously Untreated Metastatic Pancreatic Cancer
January 07, 2023
Article
A combined regimen of mitazalimab and mFOLFIRINOX resulted in a 52% objective response rate among 23 patients with metastatic pancreatic cancer.
Frontline Durvalumab Does Not Elicit Significant OS Improvement in Advanced, PD-L1-High NSCLC
December 29, 2022
Article
In the PEARL trial, monotherapy with durvalumab did not deliver a statistically significant improvement in overall survival vs platinum-based chemotherapy as frontline treatment in patients with PD-L1-high stage IV non–small cell lung cancer.
Sintilimab/Chemotherapy Regimen Boosts Progression-Free Survival in EGFR-Mutated NSCLC
November 05, 2022
Article
After 13.1 months of follow-up, the median progression-free survival in patients with EGFR-mutant non–small cell lung cancer who received a sintilimab-based regimen was 5.5 months.
5-Year Findings Support Xevinapant Plus Chemotherapy in Locally Advanced Head and Neck Cancer
October 28, 2022
Article
A presentation at the 2022 ESMO Congress found that xevinapant plus chemoradiotherapy decreased the risk of death by twice that of placebo for patients with unresectable, locally advanced head and neck squamous cell carcinoma.
Mirvetuximab Soravtansine Associated with Fewer GI Toxicities Than Chemotherapy in Advanced Ovarian Cancer
October 18, 2022
Article
An analysis of patient-reported outcomes showed that patients with advanced ovarian cancer experienced fewer abdominal or gastrointestinal toxicities with mirvetuximab soravtansine than with chemotherapy.
Avelumab/Axitinib Combo May Unlock New Treatment Direction for Rare Thymic Epithelial Tumors
October 16, 2022
Article
Phase 2 findings indicate that a combination of avelumab and axitinib may draw promising responses in patients with advanced type B3 thymoma and thymic carcinoma.
Frontline Ibrutinib Plus Venetoclax Reduces Relapse in Elderly Patients with Chronic Lymphocytic Leukemia
October 15, 2022
Article
A subgroup of the phase 3 GLOW trial revealed a unique relationship between undetectable minimal residual disease status and progression-free survival in elderly or unfit patients with chronic lymphocytic leukemia who received ibrutinib plus venetoclax.
Tivozanib Outperforms Sorafenib in Extending Overall Survival in Advanced RCC
October 12, 2022
Article
Tivozanib, an oral VEGF inhibitor, improved overall survival in patients with relapsed or refractory, advanced renal cell carcinoma.
EphrinB2 Inhibition With PD-1/PD-L1 Immunotherapy Induces Promising Responses in Progressive Metastatic Urothelial Cancer
September 04, 2022
Article
At a median follow-up of 22.9 months, patients with platinum-refractory metastatic urothelial carcinoma achieved a median overall survival of 14.6 months with EphB4-human serum albumin plus pembrolizumab.
Patients With DRD+ Metastatic Urothelial Cancer Achieve Prolonged PFS with Rucaparib Maintenance Therapy
August 24, 2022
Article
Rucaparib may be a viable maintenance therapy option for patients with DNA repair–deficient positive, metastatic urothelial cancer who are unlikely to benefit from avelumab immunotherapy.